Fate Therapeutics (FATE) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to -$32.2 million.
- Fate Therapeutics' Income from Continuing Operations rose 3291.47% to -$32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$162.0 million, marking a year-over-year increase of 936.93%. This contributed to the annual value of -$193.0 million for FY2024, which is 1134.46% down from last year.
- Latest data reveals that Fate Therapeutics reported Income from Continuing Operations of -$32.2 million as of Q3 2025, which was up 3291.47% from -$34.0 million recorded in Q2 2025.
- In the past 5 years, Fate Therapeutics' Income from Continuing Operations ranged from a high of -$24.9 million in Q1 2023 and a low of -$84.6 million during Q3 2022
- Its 5-year average for Income from Continuing Operations is -$52.0 million, with a median of -$46.9 million in 2024.
- Its Income from Continuing Operations has fluctuated over the past 5 years, first plummeted by 10901.28% in 2021, then surged by 6637.63% in 2023.
- Over the past 5 years, Fate Therapeutics' Income from Continuing Operations (Quarter) stood at -$69.1 million in 2021, then grew by 10.92% to -$61.5 million in 2022, then grew by 29.05% to -$43.7 million in 2023, then plummeted by 32.55% to -$57.9 million in 2024, then skyrocketed by 44.43% to -$32.2 million in 2025.
- Its Income from Continuing Operations was -$32.2 million in Q3 2025, compared to -$34.0 million in Q2 2025 and -$37.9 million in Q1 2025.